Fresenius Medical Care has successfully completed its merger with NxStage Medical, Inc.

More Info

Macon Dialysis Center Grand Opening

LAWRENCE, Mass. – (July 21, 2016) NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), is pleased to announce the grand opening of its Macon dialysis center, known as Georgia Kidney Institute (“GKI”).

“We aim to give patients their autonomy back by providing treatment options to meet each patient’s individual needs,” stated Dr. R. Ellis, Medical Director of GKI, and joint venture partner.

GKI offers flexible in-center hemodialysis and home hemodialysis using the NxStage® System One™. The center also offers peritoneal dialysis (PD), along with personalized training for home therapies. The center’s renal social worker provides patients with transplant assistance and lifestyle guidance, and the registered dietitian works with patients to craft nutritional plans tailored to their needs.

Area patients, their families and physicians are invited to attend the grand opening on Wednesday, August 3, 2016 from 5-7pm at Georgia Kidney Institute, 1625 Hardeman Avenue, Macon, GA 31201. For more information about NxStage Kidney Care centers please visit or call (478) 257-5200.

About NxStage Kidney Care

NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), is innovating a dialysis care model that is intended to support and encourage patient-centered care and provide enhanced access to the life-changing benefits of home therapy as well as flexible in-center options. By leveraging NxStage's home leadership and the innovative technology of its System One, NxStage Kidney Care is committed to helping patients take control of their dialysis and to allowing physicians the flexibility to prescribe what is truly best for their patients. For more information, please visit or call (866) 694-2707.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at and

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact:
Kristen K. Sheppard, Esq.
Tel: (978) 332-5923